1918 related articles for article (PubMed ID: 16730617)
1. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
Millard RJ; Halaska M
Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
[TBL] [Abstract][Full Text] [Related]
4. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
Haab F; Cardozo L; Chapple C; Ridder AM;
Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
6. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
7. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
Abrams P; Swift S
Eur Urol; 2005 Sep; 48(3):483-7. PubMed ID: 16005564
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
Staskin DR; Te AE
BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
[TBL] [Abstract][Full Text] [Related]
10. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Oresković S; But I; Banović M; Goldstajn MS
Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
[TBL] [Abstract][Full Text] [Related]
12. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
13. Solifenacin significantly improves all symptoms of overactive bladder syndrome.
Chapple CR; Cardozo L; Steers WD; Govier FE
Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
15. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM
BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
[TBL] [Abstract][Full Text] [Related]
16. Redefining response in overactive bladder syndrome.
Payne CK; Kelleher C
BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
[TBL] [Abstract][Full Text] [Related]
17. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
19. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
